Robert Lasser

6.4k citations

94 papers · 4.8k indexed · 4 hit papers · h-index 33

Impact in

Biological Psychiatry top 0.5%
- Tryptophan and brain disorders
Psychiatry and Mental health top 0.2%
- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Attention Deficit Hyperactivity Disorder

Papers in ⓘ

Biological Psychiatry 13
- Tryptophan and brain disorders 13
Psychiatry and Mental health 58
- Schizophrenia research and treatment 28
- Attention Deficit Hyperactivity Disorder 18
- Bipolar Disorder and Treatment 13
- Dementia and Cognitive Impairment Research 9

Co-authors: John M. Kane (5 shared papers)Stephen R. Marder (1 shared paper)Daniel R. Weinberger (1 shared paper)William T. Carpenter (1 shared paper)Nancy C. Andreasen (1 shared paper)Cynthia A. Bossie (21 shared papers)Georges M. Gharabawi (16 shared papers)Trey Sunderland (8 shared papers)
Journals: Schizophrenia Research (11 papers)The Journal of Clinical Psychiatry (8 papers)Alzheimer s & Dementia (8 papers)Biological Psychiatry (6 papers)European Neuropsychopharmacology (5 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Robert Lasser

92 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Zuranolone for the Treatment of Postpartum Depression 2023 · 93 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 American Journal of Psychiatry
2021 JAMA Psychiatry
2017 Alzheimer s Research & Therapy
2005 American Journal of Psychiatry

Peers

Countries citing papers authored by Robert Lasser

Since Specialization

Citations

This map shows the geographic impact of Robert Lasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lasser more than expected).

Fields of papers citing papers by Robert Lasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lasser. The network helps show where Robert Lasser may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Lasser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Lasser Line = papers co-authored together Robert Lasser links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 94 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus American Journal of Psychiatry ·Nancy C. Andreasen, William T. Carpenter, John M. Kane, Robert Lasser, Stephen R. Marder, Daniel R. Weinberger Hit paper breakdown →	2005	1741
2	A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease Alzheimer s Research & Therapy ·(unknown), Susanne Ostrowitzki, Robert Lasser, Ernest Dorflinger, Philip Scheltens, Frederik Barkhof, Tania Nikolcheva, Elizabeth Ashford, Sylvie Retout, Carsten Hofmann, Paul Delmar, Gregory Klein, Mirjana Andjelković, Bruno Dubois, Merçé Boada, Kaj Blennow, Luca Santarelli, Paulo Fontoura Hit paper breakdown →	2017	411
3	Trial of SAGE-217 in Patients with Major Depressive Disorder New England Journal of Medicine ·Handan Gunduz-Bruce, Christopher Silber, Inder Kaul, Anthony J. Rothschild, Robert Riesenberg, Abdul J. Sankoh, Haihong Li, Robert Lasser, Charles F. Zorumski, David R. Rubinow, Steven M. Paul, Jeffrey M. Jonas, James Doherty, Stephen Kanes	2019	161
4	Effect of Zuranolone vs Placebo in Postpartum Depression JAMA Psychiatry ·Kristina M. Deligiannidis, Samantha Meltzer‐Brody, Handan Gunduz‐Bruce, James Doherty, Jeffrey M. Jonas, Sigui Li, Abdul J. Sankoh, Christopher Silber, Andrew Campbell, Brian Werneburg, Stephen Kanes, Robert Lasser Hit paper breakdown →	2021	149
5	Lifespan Persistence of ADHD The Journal of Clinical Psychiatry ·Atilla Turgay, D. Wayne Goodman, Philip Asherson, Robert Lasser, T. Babcock, Michael L. Pucci, Russell A. Barkley, (unknown)	2012	135
6	Combining Serotonin Reuptake Inhibitors and Bupropion in Partial Responders to Antidepressant Monotherapy The Journal of Clinical Psychiatry ·J. Alexander Bodkin, Robert Lasser, James D. Wines, David M. Gardner, Ross J. Baldessarini	1997	116
7	Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection Schizophrenia Research ·Robert Lasser, Cynthia A. Bossie, Georges M. Gharabawi, John M. Kane	2005	104
8	Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation Neuropsychopharmacology ·Mark Hyman Rapaport, Georges M. Gharabawi, Carla M. Canuso, Ramy Mahmoud, Martin B. Keller, Cynthia A. Bossie, Ibrahim Turkoz, Robert Lasser, Amy Loescher, Philippe Bouhours, Fiona Dunbar, Charles B. Nemeroff	2006	104
9	Zuranolone for the Treatment of Postpartum Depression American Journal of Psychiatry ·Kristina M. Deligiannidis, Samantha Meltzer‐Brody, Bassem Maximos, E. Quinn Peeper, Marlene P. Freeman, Robert Lasser, Amy Bullock, Mona Kotecha, Sigui Li, Fiona Forrestal, Nilanjana Rana, Manny Garcia, Bridgette Leclair, James Doherty Hit paper breakdown →	2023	93
10	Longitudinal stability of CSF tau levels in Alzheimer patients Biological Psychiatry ·Trey Sunderland, Benjamin Wolozin, Douglas Galasko, James Levy, Ruth Dukoff, Marcel Bahro, Robert Lasser, Ruth Motter, Terho Lehtimäki, Peter Seubert	1999	82
11	Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study Health and Quality of Life Outcomes ·Meryl Brod, Betsy Pohlman, Robert Lasser, Paul Hodgkins	2012	73
12	Discriminant power of combined cerebrospinal fluid τ protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease1Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18–23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7–12, 1998, Los Angeles, CA, USA.1 Brain Research ·Harald Hampel, Stefan Teipel, Frank Padberg, Andreas Haslinger, Markus J. Riemenschneider, Markus Schwarz, H. U. Kötter, Michael Scheloske, Katharina Buch, Susanne Stübner, Ruth Dukoff, Robert Lasser, Norbert Müller, Trey Sunderland, Stanley I. Rapoport, Hans‐Jürgen Möller	1999	72
13	Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone European Psychiatry ·Robert Lasser, Cynthia A. Bossie, Georges M. Gharabawi, Martin R. Turner	2004	72
14	A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder The Journal of Clinical Psychiatry ·George M. Simpson, Ramy Mahmoud, Robert Lasser, Mary J. Kujawa, Cynthia A. Bossie, Ibrahim Turkoz, Steven Rodriguez, Georges M. Gharabawi	2006	71
15	Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone International Clinical Psychopharmacology ·Georges M. Gharabawi, Robert Lasser, Cynthia A. Bossie, Young Zhu, Xavier Amador	2006	61
16	Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia Schizophrenia Research ·Georges M. Gharabawi, Cynthia A. Bossie, Robert Lasser, Ibrahim Turkoz, Stephen C. Rodriguez, Guy Chouinard	2005	61
17	Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder Neuropsychopharmacology ·Manisha Madhoo, Richard S.E. Keefe, Robert M. Roth, Angelo Sambunaris, James X. Wu, Madhukar H. Trivedi, Colleen Anderson, Robert Lasser	2013	53
18	Newer Psychotropic Medication Use in Nursing Home Residents Journal of the American Geriatrics Society ·Robert Lasser, Trey Sunderland	1998	53
19	Remission in schizophrenia: Applying recent consensus criteria to refine the concept Schizophrenia Research ·Robert Lasser, Henry A. Nasrallah, Lars Helldin, J. Peuskens, John M. Kane, John Docherty, A TOLEDOTRONCO	2007	51
20	Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function The Journal of Clinical Psychiatry ·Lenard A. Adler, Bryan Dirks, Patrick Deas, Aparna Raychaudhuri, Matthew Dauphin, Robert Lasser, Richard H. Weisler	2013	51

About Robert Lasser

Robert Lasser is a scholar working on Biological Psychiatry, Psychiatry and Mental health, Behavioral Neuroscience, Pharmacology and Philosophy, having authored 94 papers that have together received 4.8k indexed citations. Recurring topics across this work include Schizophrenia research and treatment (28 papers), Treatment of Major Depression (19 papers), Attention Deficit Hyperactivity Disorder (18 papers), Tryptophan and brain disorders (13 papers), Bipolar Disorder and Treatment (13 papers), Mental Health and Psychiatry (10 papers), Alzheimer's disease research and treatments (9 papers) and Dementia and Cognitive Impairment Research (9 papers). The work is most often cited by research in Biological Psychiatry (592 citations), Psychiatry and Mental health (3.4k citations), Philosophy (1.1k citations), Behavioral Neuroscience (237 citations) and Pharmacology (927 citations). Robert Lasser has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include John M. Kane, Stephen R. Marder, Daniel R. Weinberger, William T. Carpenter, Nancy C. Andreasen, Cynthia A. Bossie, Georges M. Gharabawi, Trey Sunderland, Stephen Kanes and Young Zhu. Their work appears in journals such as Schizophrenia Research, The Journal of Clinical Psychiatry, Alzheimer s & Dementia, Biological Psychiatry and European Neuropsychopharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact